Abstract
The type and frequency of neurological manifestations of Behçet’s disease (BD) vary with ethnicity. We analyzed the neurological manifestations of BD in Japanese patients. All patients undergoing treatment at one of the two Yokohama City University hospitals from July 1991 to December 2007 and who fulfilled the Japanese criteria for BD revised in 1987 were studied retrospectively by chart review. Patients had been neurologically assessed by neurologists. We recorded neurological signs and symptoms, magnetic resonance imaging or computed tomography findings, and results of cerebrospinal fluid examinations from the records of each patient. We studied 412 patients with BD, of whom 54 (13%) had neurological involvement (neuro-Behçet’s disease: NB). NB patients included a significantly higher proportion of males (61%) than non-NB patients (42%, P = 0.009). The majority of patients (n = 38, 70%) had acute parenchymal NB, 15 (28%) had chronic progressive parenchymal NB, and 1 (2%) had the non-parenchymal type. Headache and fever were more frequently reported by patients with acute parenchymal NB. Personality changes, sphincter disturbances, involuntary movements, and ataxia occurred predominantly in patients with chronic progressive parenchymal NB. Lesions were distributed throughout the CNS, but mainly in the brainstem, white matter, and basal ganglia. Analysis of end-point clinical outcomes revealed a poor prognosis for patients with chronic progressive NB. In Japan, most NB patients have the parenchymal type, and male gender is a predisposing factor. Because of the unfavorable prognosis associated with chronic progressive NB, development of effective therapies are urgently needed.
Similar content being viewed by others
Abbreviations
- BD:
-
Behçet’s disease
- CNS:
-
Central nervous system
- CSF:
-
Cell counts in cerebrospinal fluid
- CT:
-
Computed tomography
- EDSS:
-
Expanded Disability Status Scale
- FLAIR:
-
Fluid attenuated inversion recovery
- ISG:
-
International Study Group
- MRI:
-
Magnetic resonance imaging
- MRV:
-
Magnetic resonance venography
- NB:
-
Neuro-Behçet’s disease
References
International Study Group for Behcet’s Disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080
Akman-Demir G, Serdaroglu P, Tasci B (1999) Clinical patterns of neurological involvement in Behcet’s disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain 122(Pt 11):2171–2182
Al-Araji A, Kidd DP (2009) Neuro-Behcet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol 8:192–204
Al-Araji A, Sharquie K, Al-Rawi Z (2003) Prevalence and patterns of neurological involvement in Behcet’s disease: a prospective study from Iraq. J Neurol Neurosurg Psychiatr 74:608–613
Aramaki K, Kikuchi H, Hirohata S (2007) HLA-B51 and cigarette smoking as risk factors for chronic progressive neurological manifestations in Behcet’s disease. Mod Rheumatol 17:81–82
Ashjazadeh N, Borhani Haghighi A, Samangooie S, Moosavi H (2003) Neuro-Behcet’s disease: a masquerader of multiple sclerosis. A prospective study of neurologic manifestations of Behcet’s disease in 96 Iranian patients. Exp Mol Pathol 74:17–22
Azizleri G, Aksungur VL, Sarica R, Akyol E, Ovul C (1994) The association of HLA-B5 antigen with specific manifestations of Behcet’s disease. Dermatology 188:293–295
Balboni A, Pivetti-Pezzi P, Orlando P, Rubini M, Selvatici R, Accorinti M, Baricordi OR, Gandini E (1992) Serological and molecular HLA typing in Italian Behcet’s patients: significant association to B51-DR5-DQw3 haplotype. Tissue Antigens 39:141–143
Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67
Chang HK, Lee SS, Bai HJ, Lee YW, Yoon BY, Lee CH, Lee YH, Song GG, Chung WT, Lee SW, Choe JY, Kim CG, Chang DK (2004) Validation of the classification criteria commonly used in Korea and a modified set of preliminary criteria for Behcet’s disease: a multi-center study. Clin Exp Rheumatol 22:S21–S26
Farah S, Al-Shubaili A, Montaser A, Hussein JM, Malaviya AN, Mukhtar M, Al-Shayeb A, Khuraibet AJ, Khan R, Trontelj JV (1998) Behcet’s syndrome: a report of 41 patients with emphasis on neurological manifestations. J Neurol Neurosurg Psychiatr 64:382–384
Gul A, Uyar FA, Inanc M, Ocal L, Tugal-Tutkun I, Aral O, Konice M, Saruhan-Direskeneli G (2001) Lack of association of HLA-B*51 with a severe disease course in Behcet’s disease. Rheumatology (Oxford) 40:668–672
Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tuzun Y, Senocak M, Yazici H (1997) Azathioprine in Behcet’s syndrome: effects on long-term prognosis. Arthritis Rheum 40:769–774
Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kotter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stubiger N, Yurdakul S, Yazici H (2008) EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 67:1656–1662
Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kotter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stubiger N, Yurdakul S, Yazici H (2009) Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis 68:1528–1534
Hirohata S (2008) Histopathology of central nervous system lesions in Behcet’s disease. J Neurol Sci 267:41–47
Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, Hashimoto T (1997) Cerebrospinal fluid interleukin-6 in progressive Neuro-Behcet’s syndrome. Clin Immunol Immunopathol 82:12–17
Hirohata S, Kikuchi H (2003) Behcet’s disease. Arthritis Res Ther 5:139–146
Houman MH, Neffati H, Braham A, Harzallah O, Khanfir M, Miled M, Hamzaoui K (2007) Behcet’s disease in Tunisia. Demographic, clinical and genetic aspects in 260 patients. Clin Exp Rheumatol 25:S58–S64
Ikeda K, Abe M, Iwasaki Y, Kinoshita M (1996) Neuro-Behcet’s disease in Japan. Neurology 47:614–615
Joseph FG, Scolding NJ (2007) Neuro-Behcet’s disease in Caucasians: a study of 22 patients. Eur J Neurol 14:174–180
Kidd D, Steuer A, Denman AM, Rudge P (1999) Neurological complications in Behcet’s syndrome. Brain 122(Pt 11):2183–2194
Kikuchi H, Aramaki K, Hirohata S (2008) Effect of infliximab in progressive neuro-Behcet’s syndrome. J Neurol Sci 272:99–105
Kilmartin DJ, Finch A, Acheson RW (1997) Primary association of HLA-B51 with Behcet’s disease in Ireland. Br J Ophthalmol 81:649–653
Kocer N, Islak C, Siva A, Saip S, Akman C, Kantarci O, Hamuryudan V (1999) CNS involvement in neuro-Behcet syndrome: an MR study. AJNR Am J Neuroradiol 20:1015–1024
Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H (1999) Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology 106:586–589
Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, Yurdakul S, Yazici H (2003) The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60–76
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452
Lakhanpal S, Tani K, Lie JT, Katoh K, Ishigatsubo Y, Ohokubo T (1985) Pathologic features of Behcet’s syndrome: a review of Japanese autopsy registry data. Hum Pathol 16:790–795
Lannuzel A, Lamaury I, Charpentier D, Caparros-Lefebvre D (2002) Neurological manifestations of Behcet’s disease in a Caribbean population: clinical and imaging findings. J Neurol 249:410–418
Lee SH, Yoon PH, Park SJ, Kim DI (2001) MRI findings in neuro-behcet’s disease. Clin Radiol 56:485–494
Lo Monaco A, La Corte R, Caniatti L, Borrelli M, Trotta F (2006) Neurological involvement in North Italian patients with Behcet disease. Rheumatol Int 26:1113–1119
Margaglione M, Brancaccio V, Giuliani N, D’Andrea G, Cappucci G, Iannaccone L, Vecchione G, Grandone E, Di Minno G (1998) Increased risk for venous thrombosis in carriers of the prothrombin G−> A20210 gene variant. Ann Intern Med 129:89–93
Mizuki N, Ohno S, Tanaka H, Sugimura K, Seki T, Kera J, Inaba G, Tsuji K, Inoko H (1992) Association of HLA-B51 and lack of association of class II alleles with Behcet’s disease. Tissue Antigens 40:22–30
Mizushima Y (1988) Recent research into Behcet’s disease in Japan. Int J Tissue React 10:59–65
Ricart JM, Vaya A, Todoli J, Calvo J, Villa P, Estelles A, Espana F, Santaolaria M, Corella D, Aznar J (2006) Thrombophilic risk factors and homocysteine levels in Behcet’s disease in eastern Spain and their association with thrombotic events. Thromb Haemost 95:618–624
Ro A, Hara M, Takada A (1999) The factor V Leiden mutation and the prothrombin G20210A mutation was not found in Japanese patients with pulmonary thromboembolism. Thromb Haemost 82:1769
Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behcet’s disease. N Engl J Med 341:1284–1291
Sbai A, Wechsler B, Duhaut P, Du-Boutin LT, Amoura Z, Cacoub P, Godeau P, Piette JC (2003) Neuro-Behcet’s disease (isolated cerebral thrombophlebitis excluded). Clinical pattern, prognostic factors, treatment and long term follow-up. Adv Exp Med Biol 528:371–376
Serdaroglu P (1998) Behcet’s disease and the nervous system. J Neurol 245:197–205
Silingardi M, Salvarani C, Boiardi L, Accardo P, Iorio A, Olivieri I, Cantini F, Salvi F, La Corte R, Triolo G, Ciccia F, Ghirarduzzi A, Filippini D, Paolazzi G, Iori I (2004) Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behcet’s disease and deep vein thrombosis. Arthritis Rheum 51:177–183
Siva A, Altintas A, Saip S (2004) Behcet’s syndrome and the nervous system. Curr Opin Neurol 17:347–357
Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, Kocer N, Yazici H (2001) Behcet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 248:95–103
Soylu M, Ersoz TR, Erken E (1992) The association between HLA B5 and ocular involvement in Behcet’s disease in southern Turkey. Acta Ophthalmol (Copenh) 70:786–789
Svensson PJ, Dahlback B (1994) Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330:517–522
Takamiya O, Ishida F, Kodaira H, Kitano K (1995) APC-resistance and Mnl I genotype (Gln 506) of coagulation factor V are rare in Japanese population. Thromb Haemost 74:996
Tursen U, Gurler A, Boyvat A (2003) Evaluation of clinical findings according to sex in 2313 Turkish patients with Behcet’s disease. Int J Dermatol 42:346–351
Yazici H, Fresko I, Yurdakul S (2007) Behcet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 3:148–155
Acknowledgments
This work was supported in part by grants from Behçet’s Disease Research Committee, Research on Specific Disease of the Health Science Research Grants from the Ministry of Health, Labour, and Welfare (Y. Ishigatsubo). The source of funding had no role on the writing of the report or the decision to publish the results. The authors are greatly indebted to Mr. Tom Kiper (Yokosuka, Japan) for his review and invaluable suggestions in preparing the manuscript.
Conflict of interest statement
The authors have received no financial support or other benefits from commercial sources for the work reported here, and the authors have no other financial interests that could create a potential conflict of interest or the appearance of a conflict of interest with regard to the present study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ideguchi, H., Suda, A., Takeno, M. et al. Neurological manifestations of Behçet’s disease in Japan: a study of 54 patients. J Neurol 257, 1012–1020 (2010). https://doi.org/10.1007/s00415-010-5454-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-010-5454-2